Article
Surgery
Sivesh K. Kamarajah, Christopher J. Sonnenday, Clifford S. Cho, Timothy L. Frankel, Filip Bednar, Theodore S. Lawrence, Hari Nathan
Summary: Adjuvant radiotherapy after R0 resection of PDAC is associated with improved survival, particularly in patients with node-positive disease. This survival benefit was shown to be restricted to patients with N1 and N2 disease. Adjuvant RT should be considered in node-positive PDAC patients after R0 resection.
Article
Oncology
Maria Danieli, Francesco Barretta, Stefano Radaelli, Marco Fiore, Claudia Sangalli, Marta Barisella, Elena Palassini, Rosalba Miceli, Anna Maria Frezza, Dario Callegaro, Paola Collini, Paolo Giovanni Casali, Silvia Stacchiotti, Alessandro Gronchi
Summary: This study explored the correlation between pathological and radiological response to preoperative treatments and outcome in surgically treated patients with myxofibrosarcoma and undifferentiated pleomorphic sarcoma. The results showed that the percentage of visible residual tumor had a greater impact on survival and disease-free survival than the size reduction of the tumor, especially in patients receiving neoadjuvant chemotherapy or radiotherapy.
Review
Oncology
Mai-Kim Gervais, Dario Callegaro, Alessandro Gronchi
Summary: Soft-tissue sarcomas are rare tumors that originate from mesenchymal tissues. They present a heterogeneous group with over 50 types, making clinical trial development challenging. Decisions regarding neoadjuvant or adjuvant chemotherapy and radiation therapy are based on current trial evidence and multidisciplinary clinical judgment.
JOURNAL OF SURGICAL ONCOLOGY
(2022)
Article
Oncology
Michael Zeidman, Hank Schmidt, J. Jaime Alberty-Oller, Kereeti V. Pisapati, Soojin Ahn, Madhu Mazumdar, Meng Ru, Erin Moshier, Elisa Port
Summary: Neoadjuvant therapy for T1 N0 HER2 + BC increased over the study period, with the most rapid increase seen in clinical T1c tumors. This trend may be consistent with secular change in Pertuzumab treatment following FDA approval in 2013.
BREAST CANCER RESEARCH AND TREATMENT
(2021)
Review
Oncology
Lauren Brown, Samer A. Naffouje, Christine Sam, Christine Laronga, M. Catherine Lee
Summary: This study analyzed the performance of NAST in female patients aged 70 to 89 with HER2+ or TNBC. The results showed that NAST combined with surgical resection has significant therapeutic effects on septuagenarians and octogenarians, but decline during therapy in NAST recipients was associated with poorer overall survival outcomes.
BREAST CANCER RESEARCH AND TREATMENT
(2022)
Article
Oncology
Henry M. Kuerer, Benjamin D. Smith, Savitri Krishnamurthy, Wei T. Yang, Vicente Valero, Yu Shen, Heather Lin, Anthony Lucci, Judy C. Boughey, Richard L. White, Emilia J. Diego, Gaiane M. Rauch
Summary: This study aims to evaluate whether radiotherapy alone can replace breast surgery in early-stage triple-negative breast cancer or HER2-positive breast cancer patients who have achieved pathological complete response through image-guided vacuum-assisted core biopsy.
Article
Oncology
Rita A. Mukhtar, Tanya L. Hoskin, Elizabeth B. Habermann, Courtney N. Day, Judy C. Boughey
Summary: Primary surgery remains the most common treatment strategy for patients with ILC. However, there was a slight decrease in NAC use while a small increase in long-course NET was observed. Long-course NET was associated with increased rates of BCS and less extensive axillary surgery in specific patient populations.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Surgery
Sarah R. Kaslow, Katherine Prendergast, Gerardo A. Vitiello, Leena Hani, Russell S. Berman, Ann Y. Lee, Camilo Correa-Gallego
Summary: This study investigated the patterns of systemic treatment in patients with duodenal adenocarcinoma and compared the overall survival of patients receiving neoadjuvant therapy, surgery alone, and adjuvant therapy. The results showed that patients with locally advanced disease who received systemic treatment had longer survival and lower mortality rates, suggesting the underutilization of adjuvant therapy in patients who met the National Comprehensive Cancer Network guidelines.
Review
Immunology
Qing Li, Ting Liu, Zhenyu Ding
Summary: Esophageal cancer is one of the most common cancers worldwide, especially in China. Current treatment methods have limited efficacy, necessitating the exploration of new treatment strategies. Immunotherapy has emerged as a promising approach and has been shown to significantly improve survival rates in cancer patients. Combining chemotherapy and/or radiotherapy with immunotherapy may have a synergistic antitumor effect.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Georges F. Hatoum, H. Thomas Temple, Silvio A. Garcia, Yi Zheng, Fouad Kfoury, Jill Kinley, Xiaodong Wu
Summary: This study reported a successful case of a large extremity soft tissue sarcoma (2933 cc) treated with a novel approach of interdigitating high-dose LATTICE radiation therapy (LRT) with standard radiation therapy as a neoadjuvant treatment to surgery. The patient tolerated the radiation therapy regimen well and achieved a negative surgical margin and over 95% necrosis of the total tumor volume. The study demonstrated the feasibility of interdigitating multiple sessions of high-dose LATTICE radiation treatments with standard neoadjuvant radiation therapy for soft tissue sarcoma.
CANCER MANAGEMENT AND RESEARCH
(2023)
Article
Gastroenterology & Hepatology
Casper W. F. van Eijck, Dana A. M. Mustafa, Disha Vadgama, Noel F. C. C. de Miranda, Bas Groot Koerkamp, Geertjan van Tienhoven, Sjoerd H. van der Burg, Nuria Malats, Casper H. J. van Eijck, Dutch Pancreatic Canc Grp DPCG
Summary: This study investigates the impact of sex disparities on clinical outcomes and tumor immune profiles in patients with pancreatic ductal adenocarcinoma (PDAC). The study found that women who underwent resection preceded by neoadjuvant chemoradiotherapy had a higher overall survival rate compared to men, possibly due to their heightened sensitivity to gemcitabine-based treatment and lower levels of protumoral M2 macrophages in the tumor microenvironment.
Article
Oncology
Thais Reif de Paul, Knut Magne Augestad, Ravi P. Kiran, Deborah S. Keller
Summary: In patients with rectal cancer resected with clear margins but positive pathologic CRM, adjuvant chemotherapy significantly improved overall survival rates. Treatment at an academic/research facility, minimally invasive surgery, well-differentiated tumors, absence of perineural invasion, and receiving adjuvant chemotherapy were all independently associated with improved survival.
Article
Oncology
Gabriella N. N. Tortorello, Eric H. H. Li, Cimarron E. E. Sharon, Kevin L. L. Ma, Robert G. G. Maki, John T. T. Miura, Douglas L. L. Fraker, Ronald P. P. DeMatteo, Giorgos C. C. Karakousis
Summary: This study analyzed data from 2656 patients with high-grade retroperitoneal sarcoma and found that neoadjuvant chemotherapy did not confer a survival advantage in 5-year overall survival. The authors called for more prospective randomized controlled studies to confirm this finding.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Francesca De Felice, Vincenzo Tombolini, Enrico Cortesi
Summary: Locally advanced rectal cancer requires a multidisciplinary management involving neoadjuvant radiotherapy, conservative surgery, and chemotherapy. Recent studies have examined the potential benefits of altering the sequencing or intensity of the standard trimodal therapy components, with a focus on the clinical significance of total neoadjuvant treatment. More long-term results and prospective studies are needed to accurately determine the clinical benefits and establish the role of total neoadjuvant therapy in locally advanced rectal cancer.
TRANSLATIONAL ONCOLOGY
(2021)
Article
Oncology
Hisaki Aiba, Kunihiro Ikuta, Kunihiro Asanuma, Katsuhisa Kawanami, Satoshi Tsukushi, Akihiko Matsumine, Daisuke Ishimura, Akihito Nagano, Yoji Shido, Eiji Kozawa, Kenji Yamada, Junji Wasa, Hiroaki Kimura, Takao Sakai, Hideki Murakami, Tomohisa Sakai, Tomoki Nakamura, Yoshihiro Nishida
Summary: This study investigated the effect of neoadjuvant therapy on highly malignant soft tissue tumors with tail-like lesions. The regression of lesions was related to the necrosis rate of the main part of the tumor but did not directly impact achieving surgery with a negative margin or improvements in oncological outcomes. A more comprehensive evaluation is necessary to elaborate on surgical strategy.
Review
Urology & Nephrology
Luca F. Valle, Eric J. Lehrer, Daniela Markovic, David Elashoff, Rebecca Levin-Epstein, R. Jeffery Karnes, Robert E. Reiter, Matthew Rettig, Jeremie Calais, Nicholas G. Nickols, Robert T. Dess, Daniel E. Spratt, Michael L. Steinberg, Paul L. Nguyen, Brian J. Davis, Nicholas G. Zaorsky, Amar U. Kishan
Summary: In the management of locally recurrent prostate cancer after definitive radiotherapy, salvage treatment modalities show similar 5-yr recurrence-free survival rates compared to RP, but reirradiation may result in lower toxicity.
Article
Oncology
Rebecca G. Levin-Epstein, Naomi Y. Jiang, Xiaoyan Wang, Shrinivasa K. Upadhyaya, Sean P. Collins, Simeng Suy, Nima Aghdam, Constantine Mantz, Alan J. Katz, Leszek Miszczyk, Aleksandra Napieralska, Agnieszka Namysl-Kaletka, Nicholas Prionas, Hilary Bagshaw, Mark K. Buyyounouski, Minsong Cao, Nzhde Agazaryan, Audrey Dang, Ye Yuan, Patrick A. Kupelian, Nicholas G. Zaorsky, Daniel E. Spratt, Osama Mohamad, Felix Y. Feng, Brandon A. Mahal, Paul C. Boutros, Arun U. Kishan, Jesus Juarez, David Shabsovich, Tommy Jiang, Sartajdeep Kahlon, Ankur Patel, Jay Patel, Nicholas G. Nickols, Michael L. Steinberg, Donald B. Fuller, Amar U. Kishan
Summary: This study evaluated the dose-response relationships for prostate-specific antigen decay and biochemical recurrence among different SBRT dose regimens, finding that dose escalation was associated with greater prostate ablation and PSA decay, and dose escalation to 40/5 was associated with improved biochemical recurrence-free survival.
RADIOTHERAPY AND ONCOLOGY
(2021)
Review
Oncology
Eric J. Lehrer, Raj Singh, Ming Wang, Vernon M. Chinchilli, Daniel M. Trifiletti, Piet Ost, Shankar Siva, Mao-bin Meng, Leila Tchelebi, Nicholas G. Zaorsky
Summary: The meta-analysis shows that stereotactic ablative radiotherapy is relatively safe and clinically beneficial in patients with oligometastatic cancer, with low rates of toxic effects and acceptable survival rates. Further research is needed to validate these findings.
Review
Oncology
Tru-Khang T. Dinh, Timur Mitin, Hilary P. Bagshaw, Karen E. Hoffman, Clara Hwang, R. Jeffrey Karnes, Amar U. Kishan, Stanley L. Liauw, Shane Lloyd, Louis Potters, Timothy N. Showalter, Al V. Taira, Neha Vapiwala, Nicholas G. Zaorsky, Anthony V. D'Amico, Paul L. Nguyen, Brian J. Davis
Summary: The review examines the appropriate use of radiation therapy for MIBC patients, identifying different clinical variants and areas of controversy through literature review and expert panel analysis, including radiation therapy dose, techniques, and chemotherapy choices.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Article
Oncology
Nicholas G. Zaorsky, Menglu Liang, Rutu Patel, Christine Lin, Leila T. Tchelebi, Kristina B. Newport, Edward J. Fox, Ming Wang
Summary: The study proposed a predictive model to help identify patients at highest risk of death after palliative radiotherapy, guiding medical professionals in choosing treatments aligned with patient choices and prognosis. Several risk factors predicting survival were identified, including metastases location, age, tumor primary, gender, comorbidity score, and radiotherapy site. The study created and validated a nomogram to predict survival in patients receiving palliative radiotherapy during their first course of treatment.
RADIOTHERAPY AND ONCOLOGY
(2021)
Letter
Urology & Nephrology
Rohann J. M. Correa, Alexander V. Louie, Nicholas G. Zaorsky, Eric J. Lehrer, Rodney Ellis, Lee Ponsky, Irving Kaplan, Anand Mahadevan, William Chu, Anand Swaminath, Raquibul Hannan, Hiroshi Onishi, Bin S. Teh, Alexander Muacevic, Simon S. Lo, Michael Staehler, Shankar Siva
EUROPEAN UROLOGY FOCUS
(2021)
Article
Oncology
Leila T. Tchelebi, Biyi Shen, Ming Wang, Niraj J. Gusani, Vonn Walter, Ross Abrams, Vivek Verma, Nicholas G. Zaorsky
Summary: For select cancer patients, treatment with curative radiation at higher volume facilities is associated with improved survival. In particular, patients receiving radiation therapy in the definitive setting without surgery may benefit most from treatment at high-volume centers.
Article
Oncology
Nicholas G. Zaorsky, Xi Wang, Sara M. Garrett, Eric J. Lehrer, Christine Lin, David J. DeGraff, Daniel E. Spratt, Daniel M. Trifiletti, Amar U. Kishan, Timothy N. Showalter, Henry S. Park, Jonathan T. Yang, Vernon M. Chinchilli, Ming Wang
Summary: This project aimed to redefine staging of metastatic cancer, identified five metastatic phenotypes through latent class analysis, and found long-term survivors. All metastatic cancer is considered as Stage IV disease.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Review
Oncology
Nicholas G. Zaorsky, Taylor Allenby, John Lin, Jennifer Rosenberg, Nicole L. Simone, Kathryn H. Schmitz
Summary: Exercise therapy combined with radiation therapy has a positive impact on the safety, feasibility, and treatment efficacy for patients, improving quality of life, reducing fatigue, enhancing mood and reducing anxiety, while also improving physical function and exercise capacity.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Article
Oncology
Tommy Jiang, Daniela Markovic, Jay Patel, Jesus E. Juarez, Ting Martin Ma, David Shabsovich, Nicholas G. Nickols, Robert E. Reiter, David Elashoff, Matthew B. Rettig, Nicholas G. Zaorsky, Daniel E. Spratt, Amar U. Kishan
Summary: This study compared different forms of radiation therapy for localized prostate cancer and found that dose escalation alone did not significantly improve 5-year outcomes, while adding long-term androgen deprivation therapy (ADT) significantly improved patient-specific mortality and distant metastasis rates.
PROSTATE CANCER AND PROSTATIC DISEASES
(2022)
Review
Medicine, General & Internal
Giang L. Ha, Eric J. Lehrer, Ming Wang, Emma Holliday, Reshma Jagsi, Nicholas G. Zaorsky
Summary: Despite equal numbers of men and women entering medical school, women are underrepresented in the upper echelons of academic medicine and receive less compensation and research funding. Studies have shown that women consistently have lower h-indexes than men across various specialties and academic ranks. Future research is needed to understand the causes of these differences and promote gender equality in academic medicine.
Meeting Abstract
Oncology
Eric Lehrer, Kelsey Stoltzfus, Brianna Jones, Niraj Gusani, Vonn Walter, Ming Wang, Daniel Trifiletti, Shankar Siva, Alexander Louie, Nicholas Zaorsky
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
(2021)
Meeting Abstract
Oncology
Steven Hatten, Eric Lehrer, Jenn Liao, Mike Sha, Daniel Trifiletti, Shankar Siva, Sean McBride, David Palma, Sheldon Holder, Nicholas Zaorsky
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
(2021)
Meeting Abstract
Urology & Nephrology
Tommy Jiang, Daniela Markovic, Jay Patel, Jesus Juarez, Martin Ma, David Shabsovich, Nicholas Zaorsky, Nicholas Nickols, Robert Reiter, David Elashoff, Matthew Rettig, Daniel Spratt, Amar Kishan
JOURNAL OF UROLOGY
(2021)
Article
Medicine, General & Internal
Oliver D. Mrowczynski, Monali Vasekar, Edward Fox, Kimberly Harbaugh, Dawit Aregawi, Colette Pameijer, Nicholas Zaorsky, Russell Payne, Elias Rizk
Summary: Neurofibromatosis type 1 (NF1) is a common inherited neurological disorder that can lead to the formation of neurofibromas. The case described a patient with NF1 who experienced severe complications, underwent surgical treatment, chemotherapy, and radiation, but ultimately developed lung metastases.
CUREUS JOURNAL OF MEDICAL SCIENCE
(2021)